Regulating off-label drug use--rethinking the role of the FDA.
about
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMePreventive pharmacologic treatments for episodic migraine in adultsPharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.Regulating off-label drug use in India: The arena for concernPharmacotherapy of schizophrenic patients: preponderance of off-label drug useUtilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.SWinning a Won Game: Caffeine Panacea for Obesity SyndemicPrevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities.Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital recordsPimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling.Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012.Off-label prescribing: a call for heightened professional and government oversightThe use of observational health-care data to identify and report on off-label use of biopharmaceutical products.Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.Off-label use of gastrointestinal medications in the intensive care unit.Off-label drug use in Psychiatry Outpatient Department: A prospective study at a Tertiary Care Teaching HospitalPrevalence and factors associated with off-label antidepressant prescriptions for insomniaBevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.Off-label use in Germany - a current appraisal of gynaecologic university departments.A Review of Pharmacovigilance.Ten common questions (and their answers) about off-label drug use.Antiepileptic use for epilepsy and nonepilepsy disorders: A population-based study (1998-2013).A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs.Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mountColon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications.Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.Generating genome-scale candidate gene lists for pharmacogenomics.Problematizing 'drugs': A cultural assessment of recreational pharmaceutical use among young adults in the USSpine care: evaluation of the efficacy and cost of emerging technology.Diagnosis, assessment, and treatment of hypersexuality.Towards evidence-based pharmacotherapy in children.Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.Off-label use of drugs and medical devices: a review of policy implications.Off-label prescribing in older patients.
P2860
Q24595345-E1887EBD-34C1-4ADD-A2AE-A1AC206139BAQ24630992-371F10E4-A17E-4B78-A7B1-4D74C7BEB471Q26776479-9C6ECD46-2AA1-4B52-B0D6-FFD41C84D473Q26801036-43F07E28-717C-4C87-A3EF-91D683957AF9Q28473574-E30AA260-0465-48CC-90E8-6C365516ADFEQ28538618-4EF6AF4A-1AA6-4333-8F96-461A69CBFDC0Q29540785-4B68B9FB-4683-4EF9-9969-CE76075F4BB1Q31035145-155C0850-E0EA-4925-86A9-1ED4ED136744Q33417608-04D2B5E7-E894-4208-B762-C6B31F4238FCQ33561818-9A745070-6720-484A-A026-5101287D92D0Q33571590-44B4B4D9-981C-47F0-813D-33A965F606E5Q33600352-A0F335A2-8B24-422E-8972-1AF6193967A1Q33610481-B22E8DAF-9CD7-4A43-86EB-582B1D5FF4B1Q33720862-A4A2919E-7209-425C-A87F-978E2CB997DDQ34219300-A5C38668-8E4A-4779-ABC1-1E8C55A18C2FQ34680866-3ABF4F30-7F90-41DB-BD13-780572A2385CQ34996953-F1039D5D-3C88-4BE0-8AF1-DE3F4C934942Q35074155-C5CFBFA7-BCF3-4B2D-8240-8986128C6770Q35169598-7AD03439-B6DC-4517-9F5D-4FA7CA856E00Q35187003-759EF87C-F4CB-412A-A87E-A27FAFA77825Q35705156-D8D17A54-788C-4AED-960C-9E2EA571A67BQ35894579-1C4BACD4-2365-4E0D-97F4-26788E78992FQ35958959-B91425A1-885E-401A-A1C8-68C47A403551Q36345024-8CE80888-F8B8-4146-8C3A-9A2E7926D837Q36512832-EA058E86-7E8F-4380-9E67-F87A24A149B1Q36661735-B0FF881F-CB2A-435E-BF9D-A968C4A9E3FFQ36904270-070E7BB5-9363-414B-8103-FFF58791ACDFQ36983443-D4837874-4F96-4ECA-9FD0-6A68FD33DA8FQ37030161-638E9D79-467E-451B-8AEE-8C61549611F7Q37238303-4FA0494E-75BC-4506-8CA8-A394C8AEF953Q37248061-EA926DB8-0049-46E7-827E-E0CA79F9DC2FQ37311193-FD9BCD34-669A-4923-B010-50725E023539Q37466913-6ACC7384-1657-48A7-BBDF-05B60F5ECF34Q37627508-C66C6136-EF37-4A56-923D-678F88723317Q37722629-086B7B57-D46D-43E9-B89B-96383FA24957Q37825584-27FE2050-B5A1-4916-B7BA-99B517DE5D8FQ37943781-F3569295-3C28-4BB8-A645-309FBE152C45Q37968148-1A583BB6-BB63-41AA-95EB-2FF06C0C5DBEQ37999651-BE22F2F2-18A0-4751-BD6A-98D92A04B739Q38014122-03D7C0AB-737F-4994-BDAF-38A80378F8B0
P2860
Regulating off-label drug use--rethinking the role of the FDA.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Regulating off-label drug use--rethinking the role of the FDA.
@ast
Regulating off-label drug use--rethinking the role of the FDA.
@en
Regulating off-label drug use--rethinking the role of the FDA.
@nl
type
label
Regulating off-label drug use--rethinking the role of the FDA.
@ast
Regulating off-label drug use--rethinking the role of the FDA.
@en
Regulating off-label drug use--rethinking the role of the FDA.
@nl
prefLabel
Regulating off-label drug use--rethinking the role of the FDA.
@ast
Regulating off-label drug use--rethinking the role of the FDA.
@en
Regulating off-label drug use--rethinking the role of the FDA.
@nl
P356
P1476
Regulating off-label drug use--rethinking the role of the FDA.
@en
P2093
Randall S Stafford
P304
P356
10.1056/NEJMP0802107
P407
P577
2008-04-01T00:00:00Z